Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
Atrial fibrillation is the most common cardiac arrhythmia and is associated with increased mortality and morbidity. Conversion to sinus rhythm is usually appropriate in patients with acute, symptomatic atrial fibrillation in order to reduce symptoms and prevent complications. Electrical cardioversion is the most used and widespread technique, but requires deep sedation and a fasting state. Pharmacological alternatives are burdened by a delayed onset of action and potential proarrhythmic effects. Therefore, new therapeutic options are being sought. Among those, vernakalant, showed a good efficacy profile and a short onset of action, but with conflicting evidence regarding potential serious adverse events. This drug profile will summarize the pharmacology behind this new drug and review recent evidence in terms of safety and efficacy.
['Guerra|Federico|F|', 'Matassini|Maria Vittoria|MV|', 'Scappini|Lorena|L|', 'Urbinati|Alessia|A|', 'Capucci|Alessandro|A|']
D000840:Anisoles D000889:Anti-Arrhythmia Agents D001281:Atrial Fibrillation D004554:Electric Countershock D006801:Humans D007262:Infusions, Intravenous D011759:Pyrrolidines
vernakalant atrial fibrillation cardioversion anti-arrhythmic drugs ion-channels rhythm control